Cargando…
Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro
Here we report the synthesis and in vitro characterization of a redox-sensitive, magnetically inducible nanoparticle carrier system based on the doxorubicin (DOX) drug delivery model. Each quantal nanocarrier unit consists of a magnetite Fe(3)O(4) nanoparticle core that is further encapsulated in se...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499231/ https://www.ncbi.nlm.nih.gov/pubmed/31110964 http://dx.doi.org/10.3389/fonc.2019.00250 |
_version_ | 1783415766469574656 |
---|---|
author | Xia, Kun-kun Lyu, Yong Yuan, Wei-tang Wang, Gui-xian Stratton, Harrison Zhang, Shui-jun Wu, Jie |
author_facet | Xia, Kun-kun Lyu, Yong Yuan, Wei-tang Wang, Gui-xian Stratton, Harrison Zhang, Shui-jun Wu, Jie |
author_sort | Xia, Kun-kun |
collection | PubMed |
description | Here we report the synthesis and in vitro characterization of a redox-sensitive, magnetically inducible nanoparticle carrier system based on the doxorubicin (DOX) drug delivery model. Each quantal nanocarrier unit consists of a magnetite Fe(3)O(4) nanoparticle core that is further encapsulated in self-assembled micelles of the redox-responsive polyethylene glycol derivative, DSPE-SS-mPEG. The nanocarrier system was prepared using a combination of ultrasonication and dialysis to produce the microenvironment sensitive delivery system. The final synthesized and DOX-loaded magnetic nanocarriers had an average size of ~150 nm when assembled with a 6.9% DOX payload. The release rate of DOX from these redox-responsive magnetic nanocarriers was shown to be accelerated in vitro when in the presence of glutathione (GSH). Furthermore, we demonstrated that more redox-responsive magnetic nanocarriers could be taken up by HeLa cells when a local magnetic field was applied. Once internalized within a cell, the micelles of the outer nanocarrier complex were broken down in the presence of higher concentrations of GSH, which accelerated the release of DOX. This produces a particle with dual operating characteristics that can be controlled via a specific cellular environment coupled with an exogenously applied signal in the form of a magnetic field triggering release. |
format | Online Article Text |
id | pubmed-6499231 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64992312019-05-20 Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro Xia, Kun-kun Lyu, Yong Yuan, Wei-tang Wang, Gui-xian Stratton, Harrison Zhang, Shui-jun Wu, Jie Front Oncol Oncology Here we report the synthesis and in vitro characterization of a redox-sensitive, magnetically inducible nanoparticle carrier system based on the doxorubicin (DOX) drug delivery model. Each quantal nanocarrier unit consists of a magnetite Fe(3)O(4) nanoparticle core that is further encapsulated in self-assembled micelles of the redox-responsive polyethylene glycol derivative, DSPE-SS-mPEG. The nanocarrier system was prepared using a combination of ultrasonication and dialysis to produce the microenvironment sensitive delivery system. The final synthesized and DOX-loaded magnetic nanocarriers had an average size of ~150 nm when assembled with a 6.9% DOX payload. The release rate of DOX from these redox-responsive magnetic nanocarriers was shown to be accelerated in vitro when in the presence of glutathione (GSH). Furthermore, we demonstrated that more redox-responsive magnetic nanocarriers could be taken up by HeLa cells when a local magnetic field was applied. Once internalized within a cell, the micelles of the outer nanocarrier complex were broken down in the presence of higher concentrations of GSH, which accelerated the release of DOX. This produces a particle with dual operating characteristics that can be controlled via a specific cellular environment coupled with an exogenously applied signal in the form of a magnetic field triggering release. Frontiers Media S.A. 2019-04-10 /pmc/articles/PMC6499231/ /pubmed/31110964 http://dx.doi.org/10.3389/fonc.2019.00250 Text en Copyright © 2019 Xia, Lyu, Yuan, Wang, Stratton, Zhang and Wu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xia, Kun-kun Lyu, Yong Yuan, Wei-tang Wang, Gui-xian Stratton, Harrison Zhang, Shui-jun Wu, Jie Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro |
title | Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro |
title_full | Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro |
title_fullStr | Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro |
title_full_unstemmed | Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro |
title_short | Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro |
title_sort | nanocarriers of fe(3)o(4) as a novel method for delivery of the antineoplastic agent doxorubicin into hela cells in vitro |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499231/ https://www.ncbi.nlm.nih.gov/pubmed/31110964 http://dx.doi.org/10.3389/fonc.2019.00250 |
work_keys_str_mv | AT xiakunkun nanocarriersoffe3o4asanovelmethodfordeliveryoftheantineoplasticagentdoxorubicinintohelacellsinvitro AT lyuyong nanocarriersoffe3o4asanovelmethodfordeliveryoftheantineoplasticagentdoxorubicinintohelacellsinvitro AT yuanweitang nanocarriersoffe3o4asanovelmethodfordeliveryoftheantineoplasticagentdoxorubicinintohelacellsinvitro AT wangguixian nanocarriersoffe3o4asanovelmethodfordeliveryoftheantineoplasticagentdoxorubicinintohelacellsinvitro AT strattonharrison nanocarriersoffe3o4asanovelmethodfordeliveryoftheantineoplasticagentdoxorubicinintohelacellsinvitro AT zhangshuijun nanocarriersoffe3o4asanovelmethodfordeliveryoftheantineoplasticagentdoxorubicinintohelacellsinvitro AT wujie nanocarriersoffe3o4asanovelmethodfordeliveryoftheantineoplasticagentdoxorubicinintohelacellsinvitro |